Latest Conference Coverage

Adapting Cognitive Tools for Clinical Trials in Down Syndrome: Elizabeth Head, PhD

The professor in the Department of Pathology and Laboratory Medicine at the University of California, Irvine, gave clinical insights on efforts to refine neuropsychological outcome measures for individuals with Down syndrome at risk for Alzheimer disease. [WATCH TIME: 3 minutes]

Highlighting Early-Stage Promising Data of AAK1 Inhibitor SAT-3247 in Duchenne Muscular Dystrophy: Phil Lambert, PhD

The chief scientific officer at Satellos Bioscience discussed phase 1 findings on SAT-3247, an oral AAK1 inhibitor, highlighting its safety, pharmacokinetics, and early translatability in Duchenne muscular dystrophy. [WATCH TIME: 7 minutes]

Advancements and Challenges in Pediatric Multiple Sclerosis Treatment: Lauren B. Krupp, MD

The director of NYU Langone's Multiple Sclerosis Comprehensive Care Center discussed the importance of early, high-efficacy treatment for pediatric MS. [WATCH TIME: 3 minutes]

Investigational Telitacicept Significantly Improves Myasthenia Gravis Outcomes in Phase 3 Study

In a late-stage trial, telitacicept demonstrated significant and rapid clinical improvements in gMG, achieving notable symptom reductions, improved quality of life, and strong safety outcomes.

Harnessing Gamma Frequencies to Modulate Alzheimer Pathology: Ralph Kern, MD, MHSc

The chief medical officer at Cognito Therapeutics provided a clinical overview on promising findings surrounding the company’s gamma sensory stimulation device in patients with Alzheimer disease. [WATCH TIME: 10 minutes]

Phase 2 RESCUE Data Show RNS60 Reduces Stroke Infarct and Improves Outcomes

High doses of RNS60 led to greater number of patients with modified Rankin scale scores between 0-2, improved EQ-5D-5L index score, and enhanced NIHSS score at each pre-specified time point over placebo.

Safety Profile of CT1812 and Its Effect on Proteomic Biomarkers of Alzheimer Disease: Mary Hamby, PhD

The vice president of research at Cognition Therapeutics provided commentary on the safety of investigational CT1812 and its role in immune response and synapse-related pathways. [WATCH TIME: 3 minutes]

A New Era in Research: Exploring Cognitive Health and Alzheimer Disease in Down Syndrome

Elizabeth Head, PhD, a professor in the Department of Pathology and Laboratory Medicine at the University of California, Irvine, shed light on the emerging research and trials surrounding the interplay between Alzheimer disease and Down syndrome.

Felix NeuroAI Wristband Demonstrates Superiority Over Sham Device in TRANQUIL Study for Essential Tremor

In late-breaking findings from the TRANQUIL study presented at AAN 2025, the wearable demonstrated significant improvements in tremor reduction and daily functioning over a sham device.

Improving Timely ALS Diagnosis With the thinkALS Toolkit: Melody Schaeffer, PhD, MPH

The senior director of mission programs at The ALS Association discussed how the thinkALS Toolkit can aid general neurologists in identifying and referring suspected cases more efficiently. [WATCH TIME: 5 minutes]

Real-World Data Reveal Concern of Infections in Efgartigimod for Myasthenia Gravis

Patients treated with efgartigimod for myasthenia gravis were found to have a higher incidence and severity of infections compared to those treated with immunoglobulins.

Building Community and Education Through the AMDAPP CME Conference: Kinsey McCartney, PA-C

The physician assistant at UCSF Movement Disorder and Neuromodulation Center reflected on the value of AMDAPP in fostering professional connection, education, and patient-centered care among movement disorder APPs. [WATCH TIME: 3 minutes]

Phase 1 Study Supports Further Development of LRRK2 Inhibitor ARV-102

ARV-102 showed dose-dependent LRRK2 degradation and favorable safety in its first-in-human trial, supporting its promise for treating LRRK2-linked neurodegenerative diseases.

Key Insights from ACTRIMS Forum 2025: Diagnostic Criteria, Imaging, and MS Subtypes

Experts discussed recent advancements in diagnostic criteria, imaging techniques, and the evolving understanding of multiple sclerosis subtypes and treatment responses. [WATCH TIME: 10 minutes]

Challenges in Treating Genetically Predisposed Alzheimer Disease: Insights from APOLLOE4

Emer MacSweeney, MD, a consultant neuroradiologist and trial investigator of the phase 3 APOLLOE4 study, provided a clinical view of the latest study findings, and the difficulties with finding treatments for APOEε4/4 carriers of Alzheimer disease.

Exploring Noninvasive Brain Stimulation for Neurorehabilitation: Roy H. Hamilton, MD, MS, FAAN

The professor of neurology at the University of Pennsylvania Perelman School of Medicine discussed the current research landscape, clinical challenges, and future directions for noninvasive neuromodulation techniques in neurorehabilitation. [WATCH TIME: 4 minutes]

Educating the Clinical Community on Differences in Alzheimer Diagnostic Criteria: Clifford Jack, MD

The neuroradiologist at Mayo Clinic provided clinical insights on the controversy with two recently published Alzheimer criteria, with one diagnosing the disease based on biomarkers alone vs clinical symptoms. [WATCH TIME: 4 minutes]

Next-Gen Gene Editing for Muscular Dystrophy: Exploring the ARCUS Approach

Cassandra Gorsuch, PhD, chief scientific officer at Precision Biosciences, discussed the company’s ARCUS gene editing platform, its innovative approach to treating Duchenne muscular dystrophy, and promising preclinical data presented at MDA 2025.

Translating Oculopharyngeal Muscular Dystrophy Research Into Clinical Application: Matthew Wicklund, MD

The professor of neurology at the University of Texas Health Science Center San Antonio discussed some of the challenges with therapeutic development for OPMD, as well as advances and barriers to gene therapy approaches. [WATCH TIME: 4 minutes]

The Key Role of Early and Balanced Blood Pressure Control in ICH Management: Kara R. Melmed, MD

The clinical associate professor of neurology and neurosurgery at NYU Langone Health emphasized the importance of rapid, targeted blood pressure reduction and bundled care to improve outcomes in patients with intracerebral hemorrhage. [WATCH TIME: 4 minutes]

AXS-07 Outperforms Other CGRP-Targeting Gepants in Meta-Analysis

Relative to previously approved therapies like rimegepant, ubrogepant, and zavegepant, AXS-07 resulted in better 2-hour pain relief, sustained pain relief, and reduced use of rescue medications.

Understanding the Cellular Drivers of MS Progression and Treatment Response: Amit Bar-Or, MD, FRCPC, FAAN, FANA

The Melissa and Paul Anderson President’s Distinguished Professor of Neurology, Perelman School of Medicine, University of Pennsylvania discussed evolving insights into the cellular immunology of multiple sclerosis. [WATCH TIME: 4 minutes]

Phase 3 Study to Test 1st Generation Antihistamine EPX-100 in Lennox-Gastaut Syndrome

Harmony Biosciences’ phase 3 study will assess EPX-100, a repurposed antihistamine, as a potential treatment for Lennox-Gastaut syndrome, targeting seizure reduction and improved outcomes.

NeuroVoices: Chitra Venkatasubramanian, MBBS, MD, MSc, FNCS, on Debating Optimal Blood Pressure Targets After Intracerebral Hemorrhage

The clinical professor of stroke neurology at Stanford University discussed the clinical rationale and evidence supporting early, intensive blood pressure lowering in patients with intracerebral hemorrhage.

Overviewing Valiltramiprosate’s Therapeutic Impact on Volumetric Imaging MRI, Diffusion Tensor Imaging in Alzheimer Disease

Murali Doraiswamy, MD, MBBS, a professor of psychiatry and geriatrics at Duke University School of Medicine, gave clinical follow-up on a pivotal analysis of the phase 3 APOLLOE4 study testing a novel therapeutic for Alzheimer disease.

ZYN002 Gel Shows Long-Term Safety and Behavioral Improvements in Fragile X Syndrome

Newly presented open-label extension results at AAN 2025 suggest that investigational ZYN002, a cannabidiol gel, may help improve irritability in children and adolescents living with Fragile X syndrome.

Advancing Preclinical Alzheimer Research Through AI and Behavioral Analysis: Stephanie R. Miller, PhD

The staff scientist at Gladstone Institutes talked about leveraging AI-driven behavioral analysis to better model and assess Alzheimer disease progression in preclinical studies. [WATCH TIME: 2 minutes]

IPX203 Boosts “Good ON” Time in Parkinson Disease, Especially in Patients on Lower Dopamine Agonist Doses

Findings from a phase 3 study revealed that patients with Parkinson disease switching to IPX203 had greater benefits in good ON time when also taking lower doses of dopamine agonists.

GLP-1 Analogs Showing Broad Neuroprotective Potential Across Neurological Disorders: Paul Edison, MBBS, PhD, FRCPI

The professor of neuroscience at the Imperial College London discussed the emerging role of GLP-1 analogs as neuroprotective agents with potential benefits in neurodegenerative conditions. [WATCH TIME: 4 minutes]

CGRP Therapies as Potential First-Line Migraine Preventive Treatment: Andrew Charles, MD

The director of the UCLA Goldberg Migraine Program discussed the advantages, evidence base, and evolving payor support for CGRP-targeting therapies as potentially a first-line option in migraine prevention. [WATCH TIME: 5 minutes]